• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Evelo Biosciences Inc.

    12/12/23 7:43:35 AM ET
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVLO alert in real time by email
    DEFA14A 1 edge20015072x2_defa14a.htm DEFA14A

     

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


     

     

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

     

     

    Filed by the Registrant  ☒

     

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under §240.14a-12

     

    Evelo Biosciences, Inc. 

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     







    Get the next $EVLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVLO

    DatePrice TargetRatingAnalyst
    11/2/2021$44.00 → $41.50Market Outperform
    JMP Securities
    11/1/2021$12.00Neutral → Buy
    Chardan Capital Markets
    6/23/2021$36.00 → $38.00Market Outperform
    JMP Securities
    6/23/2021$28.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously

      11/2/21 7:54:09 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evelo Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00

      11/1/21 8:36:16 AM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Evelo Biosciences with a new price target

      JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously

      6/23/21 1:58:41 PM ET
      $EVLO
      Biotechnology: Pharmaceutical Preparations
      Health Care